达沙替尼联合吉西他滨治疗局部晚期胰腺癌的2期安慰剂对照双盲试验
这项随机、双盲、安慰剂对照2期研究在局部晚期非转移性胰腺导管腺癌患者中比较吉西他滨联合达沙替尼与吉西他滨联合安慰剂。两组总生存无统计学显著差异(HR=1.16;95%CI:0.81-1.65;P=0.5656),次要与探索性终点亦无统计学显著差异,达沙替尼组毒性负担更高。
要点
- 吉西他滨联合达沙替尼较吉西他滨联合安慰剂未改善总生存(HR=1.16;95%CI:0.81-1.65;P=0.5656)。
- 次要与探索性终点分析同样未显示统计学显著差异。
- 达沙替尼组毒性负担高于安慰剂组。
核心结论
- 达沙替尼未能在局部晚期胰腺导管腺癌患者中显示总生存或无进展生存获益。
- 作者认为其他联合方案或试验设计可能显示Src抑制在胰腺导管腺癌治疗中的作用。
研究设计与样本
- 随机、双盲、安慰剂对照2期研究,比较吉西他滨联合达沙替尼与吉西他滨联合安慰剂。
- 人群为局部晚期、非转移性胰腺导管腺癌患者。
- 吉西他滨1000 mg/m2(30分钟静脉输注)于28天周期的第1、8、15天给药,联合每日口服100 mg达沙替尼或安慰剂片。
- 主要终点为总生存,安全性与无进展生存为次要终点。
- 探索性终点包括总缓解率、无远处转移生存、疼痛与疲乏进展及缓解率、CA19-9缓解率。
主要发现
- 两组总生存无统计学显著差异(HR=1.16;95%CI:0.81-1.65;P=0.5656)。
- 次要与探索性终点分析同样未显示统计学显著差异。
- 达沙替尼组毒性负担高于安慰剂组。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) has a high mortality rate with limited treatment options. Gemcitabine provides a marginal survival benefit for patients with advanced PDAC. Dasatinib is a competitive inhibitor of Src kinase, which is overexpressed in PDAC tumors. Dasatinib and gemcitabine were combined in a phase 1 clinical trial where stable disease was achieved in two of eight patients with gemcitabine-refractory PDAC. PATIENTS AND METHODS: This placebo-controlled, randomized, double-blind, phase II study compared the combination of gemcitabine plus dasatinib to gemcitabine plus placebo in patients with locally advanced, non-metastatic PDAC. Patients received gemcitabine 1000 mg/m2 (30-min IV infusion) on days 1, 8, 15 of a 28-day cycle combined with either 100 mg oral dasatinib or placebo tablets daily. The primary objective was overall survival (OS), with safety and progression-free survival (PFS) as secondary objectives. Exploratory endpoints included overall response rate, freedom from distant metastasis, pain and fatigue progression and response rate, and CA19-9 response rate. RESULTS: There was no statistically significant difference in OS between the two treatment groups (HR = 1.16; 95% confidence interval [CI]: 0.81-1.65; P = 0.5656). Secondary and exploratory endpoint analyses also showed no statistically significant differences. The burden of toxicity was higher in the dasatinib arm. CONCLUSIONS: Dasatinib failed to show increased OS or PFS in patients with locally advanced PDAC. Alternative combinations or trial designs may show a role for src inhibition in PDAC treatment.
引用
- Evans TRJ, Van Cutsem E, Moore MJ, et al. Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer. Ann Oncol. 2017. PMID: 27998964. doi:10.1093/annonc/mdw607
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。